• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

膀胱癌生存:女性长期预后更好。

Bladder cancer survival: Women better off in the long run.

机构信息

Department of Research, Cancer Registry of Norway, PB 5313, Majorstuen, 0304, Oslo, Norway.

Department of Research, Cancer Registry of Norway, PB 5313, Majorstuen, 0304, Oslo, Norway.

出版信息

Eur J Cancer. 2018 May;95:52-58. doi: 10.1016/j.ejca.2018.03.001. Epub 2018 Apr 7.

DOI:10.1016/j.ejca.2018.03.001
PMID:29635144
Abstract

AIM

Mortality among patients with bladder cancer is usually reported to be higher for women than men, but how the risk differs and why remain largely unexplained. We also described gender-specific differences in survival for patients with bladder cancer and estimated to what extent they can be explained by differences in T-stage distribution at the first diagnosis.

METHODS

The present study comprised all 15,129 new cases of histologically verified invasive and non-invasive urothelial carcinoma of the urinary bladder diagnosed between 1997 and 2011 as registered in the Cancer Registry of Norway. Gender-specific excess mortality risk rates and risk ratios were calculated based on a flexible parametric relative survival model adjusting for T-stage and age, allowing the effect of gender to vary over time. We also present gender-specific relative survival curves for different T-stage patterns adjusted for age.

RESULTS

Risk rates were significantly higher for women than men up to 2 years after bladder cancer diagnosis, particularly for muscle-invasive cancers. Thereafter, risk rates appeared to be higher in men. Adverse T-Stage distribution in women explained half of the unfavourable survival difference in female patients 2 years after diagnosis.

CONCLUSION

The common view of worse bladder cancer prognosis in women than in men needs to be revised. Norwegian women have a less favourable prognosis solely within the first 2 years after diagnosis, particularly when diagnosed with a muscle-invasive tumour; parts of this discrepancy can be attributed to more severe initial diagnoses in women.

摘要

目的

通常报道女性膀胱癌患者的死亡率高于男性,但风险差异如何以及原因仍在很大程度上未得到解释。我们还描述了膀胱癌患者的性别特异性生存差异,并估计了在多大程度上可以通过首次诊断时 T 分期分布的差异来解释这些差异。

方法

本研究包括 1997 年至 2011 年期间在挪威癌症登记处登记的所有 15129 例经组织学证实的浸润性和非浸润性尿路上皮膀胱癌新病例。根据调整 T 分期和年龄的灵活参数相对生存模型,计算了性别特异性超额死亡率风险率和风险比,允许性别因素随时间变化。我们还为不同 T 分期模式呈现了性别特异性相对生存曲线,这些曲线根据年龄进行了调整。

结果

在膀胱癌诊断后 2 年内,女性的风险率明显高于男性,尤其是对于肌肉浸润性癌症。此后,男性的风险率似乎更高。女性不良 T 分期分布解释了女性患者在诊断后 2 年内生存差异的一半。

结论

女性膀胱癌预后比男性差的普遍观点需要修正。挪威女性仅在诊断后 2 年内预后较差,尤其是诊断为肌肉浸润性肿瘤时;这种差异的一部分可以归因于女性更严重的初始诊断。

相似文献

1
Bladder cancer survival: Women better off in the long run.膀胱癌生存:女性长期预后更好。
Eur J Cancer. 2018 May;95:52-58. doi: 10.1016/j.ejca.2018.03.001. Epub 2018 Apr 7.
2
Bladder cancer survival: Women only fare worse in the first two years after diagnosis.膀胱癌生存率:仅在诊断后的头两年,女性的情况更糟。
Urol Oncol. 2019 Dec;37(12):853-861. doi: 10.1016/j.urolonc.2019.08.001. Epub 2019 Aug 31.
3
Sex Differences in Urothelial Bladder Cancer Survival.尿路上皮膀胱癌的生存性别差异。
Clin Genitourin Cancer. 2020 Feb;18(1):26-34.e6. doi: 10.1016/j.clgc.2019.10.020. Epub 2019 Nov 6.
4
Incidence and Survival of urothelial carcinoma of the urinary bladder in Norway 1981-2014.1981 - 2014年挪威膀胱尿路上皮癌的发病率与生存率
BMC Cancer. 2016 Oct 13;16(1):799. doi: 10.1186/s12885-016-2832-x.
5
Crude mortality and loss of life expectancy of patients diagnosed with urothelial carcinoma of the urinary bladder in Norway.挪威膀胱尿路上皮癌确诊患者的粗死亡率和预期寿命损失
Scand J Urol. 2017 Feb;51(1):38-43. doi: 10.1080/21681805.2016.1271354. Epub 2017 Jan 13.
6
Impact of sex difference on survival of bladder cancer: A population-based registry data in Japan.性别差异对膀胱癌生存的影响:来自日本的基于人群的登记数据。
Int J Urol. 2019 Jun;26(6):649-654. doi: 10.1111/iju.13955. Epub 2019 Mar 27.
7
Gender-related differences in urothelial carcinoma of the bladder: a population-based study from the Swedish National Registry of Urinary Bladder Cancer.膀胱尿路上皮癌的性别相关差异:一项基于瑞典国家膀胱癌登记处的人群研究。
Scand J Urol. 2016 Aug;50(4):292-7. doi: 10.3109/21681805.2016.1158207. Epub 2016 Mar 22.
8
Italian cancer figures--Report 2015: The burden of rare cancers in Italy.意大利癌症数据——2015年报告:意大利罕见癌症的负担
Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035.
9
Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival.根据马略卡癌症登记处收集的膀胱癌分期和与生存相关的因素对癌症特异性生存的分析。
BMC Cancer. 2021 Jun 7;21(1):676. doi: 10.1186/s12885-021-08418-y.
10
Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder.膀胱肉瘤样癌、癌肉瘤和尿路上皮癌患者的生存差异。
J Urol. 2007 Dec;178(6):2302-6; discussion 2307. doi: 10.1016/j.juro.2007.08.038. Epub 2007 Oct 15.

引用本文的文献

1
Gender disparities in bladder cancer: A population-based study on life expectancy and health spending in Asia.膀胱癌的性别差异:一项基于亚洲人群的预期寿命和医疗支出研究。
PLoS One. 2025 Jun 4;20(6):e0323803. doi: 10.1371/journal.pone.0323803. eCollection 2025.
2
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab.性别作为帕博利珠单抗治疗晚期尿路上皮癌患者生存情况的修饰因素
Sci Rep. 2025 Mar 14;15(1):8815. doi: 10.1038/s41598-025-93094-2.
3
Sex Disparities in Bladder Cancer Diagnosis and Treatment.
膀胱癌诊断与治疗中的性别差异。
Cancers (Basel). 2024 Dec 7;16(23):4100. doi: 10.3390/cancers16234100.
4
[High expression of miR-204-5p promotes malignant behaviors of bladder cancer cells by negatively regulating RAB22A].[miR-204-5p高表达通过负调控RAB22A促进膀胱癌细胞的恶性行为]
Nan Fang Yi Ke Da Xue Xue Bao. 2024 Nov 20;44(11):2235-2242. doi: 10.12122/j.issn.1673-4254.2024.11.21.
5
Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes.膀胱癌分子亚型中 T 细胞群体的浸润特征不同。
Cells. 2024 May 28;13(11):926. doi: 10.3390/cells13110926.
6
Do Fibroblast Growth Factor Receptor (FGFR) 2 and 3 Proteins Play a Role in Prognosis of Invasive Urothelial Bladder Carcinoma?成纤维细胞生长因子受体(FGFR)2和3蛋白在浸润性膀胱尿路上皮癌的预后中起作用吗?
Iran J Pathol. 2024 Winter;19(1):81-88. doi: 10.30699/IJP.2024.2012115.3180. Epub 2024 Mar 29.
7
Time-varying associations of patient and tumor characteristics with cancer survival: an analysis of SEER data across 14 cancer sites, 2004-2017.基于 SEER 数据的 14 个癌种 2004-2017 年肿瘤特征和患者特征与癌症生存的时变关联分析
Cancer Causes Control. 2024 Oct;35(10):1393-1405. doi: 10.1007/s10552-024-01888-y. Epub 2024 May 29.
8
Disparities in cause-specific mortality by race and sex among bladder cancer patients from the SEER database.SEER 数据库中膀胱癌患者按种族和性别划分的特定病因死亡率差异。
Cancer Causes Control. 2023 Jun;34(6):521-531. doi: 10.1007/s10552-023-01679-x. Epub 2023 Mar 8.
9
Radical cystectomy and urinary diversion in women: techniques, outcomes, and challenges-a narrative review.女性根治性膀胱切除术与尿流改道:技术、结果及挑战——一项叙述性综述
Transl Androl Urol. 2022 Nov;11(11):1598-1610. doi: 10.21037/tau-22-463.
10
Precision Medicine in the Treatment of Locally Advanced or Metastatic Urothelial Cancer: New Molecular Targets and Pharmacological Therapies.精准医学在局部晚期或转移性尿路上皮癌治疗中的应用:新的分子靶点与药物治疗
Cancers (Basel). 2022 Oct 21;14(20):5167. doi: 10.3390/cancers14205167.